Last reviewed 2026-05-27 · How we verify

Nopia (ROMURTIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Nopia (generic name: ROMURTIDE) is a romurtide drug. It is currently in Phase 2 development.

Nopia works by binding to and activating a specific receptor, which helps to regulate the body's response to certain stimuli.

Nopia is a small molecule modality. It is also known by the synonyms Romurtida and Romurtide.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ROMURTIDE
Drug class	romurtide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock - Nopia is the key that helps to unlock a specific response in the body. This response can help to treat certain conditions by reducing inflammation or other symptoms. By binding to its target receptor, Nopia helps to send a signal that tells the body to take a specific action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nopia CI brief — competitive landscape report
Nopia updates RSS · CI watch RSS

Frequently asked questions about Nopia

What is Nopia?

Nopia (ROMURTIDE) is a romurtide drug.

How does Nopia work?

Nopia works by binding to and activating a specific receptor, which helps to regulate the body's response to certain stimuli.

What is the generic name of Nopia?

ROMURTIDE is the generic (nonproprietary) name of Nopia.

What drug class is Nopia in?

Nopia belongs to the romurtide class. See all romurtide drugs at /class/romurtide.

What development phase is Nopia in?

Nopia is in Phase 2.

Drug class: All romurtide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing